Taking out the JNK: A window of opportunity to improve cancer therapy.
c-JUN-N-terminal kinase (JNK) signaling is a stress-induced response that enables survival of normal cells and is also utilized by cancer cells to evade therapy. Combining JNK inhibitors with standard therapies provides a potential strategy for overcoming drug resistance. Use of the optimal combination dosing and scheduling may substantially improve outcomes for cancer patients.
Cancer Research Division, Peter MacCallum Cancer Center, St. Andrew's Place, East Melbourne, VIC, Australia; Department of Pathology and The Sir Peter MacCallum Department of Oncology, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, VIC, Australia.
Petranel T
PT
Ferrao
Combination therapies; EMT; JNK signaling; dosing; drug resistance; early adaptation; phenotype-switching; scheduling; stress response